Natera, Inc. (NASDAQ:NTRA) Shares Acquired by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 3.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 566,549 shares of the medical research company's stock after buying an additional 16,678 shares during the quarter. Chevy Chase Trust Holdings LLC owned approximately 0.42% of Natera worth $80,116,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Blue Trust Inc. raised its position in shares of Natera by 223.7% during the 4th quarter. Blue Trust Inc. now owns 301 shares of the medical research company's stock worth $48,000 after purchasing an additional 208 shares during the last quarter. Principal Securities Inc. raised its holdings in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after acquiring an additional 59 shares during the last quarter. Global Retirement Partners LLC raised its holdings in shares of Natera by 55.0% during the fourth quarter. Global Retirement Partners LLC now owns 434 shares of the medical research company's stock valued at $69,000 after acquiring an additional 154 shares during the last quarter. Y Intercept Hong Kong Ltd raised its holdings in shares of Natera by 211.9% during the fourth quarter. Y Intercept Hong Kong Ltd now owns 31,144 shares of the medical research company's stock valued at $4,930,000 after acquiring an additional 21,160 shares during the last quarter. Finally, ARK Investment Management LLC raised its holdings in shares of Natera by 29.1% during the fourth quarter. ARK Investment Management LLC now owns 887,711 shares of the medical research company's stock valued at $140,525,000 after acquiring an additional 200,008 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Michael Burkes Brophy sold 2,562 shares of the business's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $138.41, for a total value of $354,606.42. Following the completion of the transaction, the chief financial officer now directly owns 75,557 shares of the company's stock, valued at $10,457,844.37. The trade was a 3.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 9,563 shares of the business's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $138.41, for a total value of $1,323,614.83. Following the completion of the transaction, the chief executive officer now directly owns 212,541 shares of the company's stock, valued at approximately $29,417,799.81. This trade represents a 4.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 59,755 shares of company stock valued at $8,898,589. 7.60% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts recently commented on NTRA shares. Piper Sandler increased their price objective on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. Wall Street Zen cut Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Robert W. Baird raised their target price on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Royal Bank Of Canada began coverage on Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price objective for the company. Finally, Barclays upped their price objective on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $184.63.

Natera Stock Performance

Natera stock traded down $0.21 during midday trading on Friday, reaching $167.96. The company's stock had a trading volume of 3,082,525 shares, compared to its average volume of 1,423,785. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The stock's 50 day simple moving average is $158.92 and its 200 day simple moving average is $158.59. The firm has a market capitalization of $22.93 billion, a PE ratio of -114.26 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The company had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. During the same period last year, the firm earned ($0.56) EPS. The company's revenue for the quarter was up 36.5% on a year-over-year basis. Equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.